Abstract 555P
Background
Approximately half of non-small cell lung cancer (NSCLC) patients are diagnosed at a metastatic stage. Molecular testing is vital for identifying druggable mutations in these patients. This prospective study aimed to assess the quality of life (QoL) of these patients and differences in QoL between patients with or without druggable mutations.
Methods
Patients newly diagnosed with stage IV NSCLC after March 2021 from the seven public oncology centres in Hong Kong were eligible. Mutation profiling was performed using next-generation sequencing with FoundationOne CDx. QoL assessments were conducted at baseline and then at 3, 6, 9, and 12 months using validated EORTC QLQ-C30 and EQ-5D-5L questionnaires.
Results
A total of 580 patients were included. Statistically significant changes in various aspects of QoL were observed over time, including global health status (QL), physical functioning (PF), role functioning (RF), emotional functioning (EF), social functioning (SF), as well as symptoms such as fatigue, pain, dyspnoea, and insomnia (all p < 0.05). There was also significant change in all 5 aspects of EQ-5D-5L and utility score over time. Overall, most improvements in functional and symptom scales were observed in the first 3-6 months’ follow-up. Among the 241 patients with at least 3 months’ follow-up, compared to those without druggable mutations, those with druggable mutations demonstrated better QL at 3- and 12-month (mean difference (MD) 6.11, p=0.04; MD 19.56, p=0.01, respectively), PF at 3-, 6-, and 12-month (MD 12.76, p=0.001; MD 14.62, p=0.01; MD 22.55, p=0.02), EF at 12-month (MD 21.76, p = 0.001), and SF at 6- and 12-month (MD 14.51, p=0.02; MD 21.86, p=0.04); improved pain at 6- and 12-month (MD 14.44, p = 0.03; MD 36.57, p = 0.02), dyspnoea at 3-month (MD 18.23, p<0.001) and appetite at 6-month (MD 15.23, p = 0.04). They also had higher utility scores at 3- and 6-month intervals (MD 0.13, p = 0.04; MD 0.23, p = 0.05).
Conclusions
In conclusion, this study demonstrated improvements in QoL and symptom relief in newly diagnosed stage IV NSCLC patients within the first 3-6 months in Hong Kong. Patients with druggable mutations generally experienced better QoL compared to those without.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Hong Kong.
Funding
Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
16P - Patient and healthcare practitioner preferences in early-stage triple-negative breast cancer treatment: A discrete choice experiment
Presenter: Jiun-I Lai
Session: Poster Display
Resources:
Abstract
17P - Initial outcomes of the ACT Now PRIME CARE for breast cancer: Prevention of Breast canceR (screening/ stage shifting) utilizing Integrated MobilE Clinics and pAtient Reported online Evaluations and Education
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
18P - Optimizing premenopausal HR+ HER2–ve eBC management in India: Insights from expert consensus
Presenter: Anitha Ramesh
Session: Poster Display
Resources:
Abstract
19P - Referral patterns among breast cancer patients in county-level hospitals in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
20P - Real-world treatment of HER2+ and HR+/HER2- early breast cancer in county areas of China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
21P - Duration of breast cancer trials: Analysis of predicted versus actual completion date
Presenter: Daniëlle Verschoor
Session: Poster Display
Resources:
Abstract
22P - Impact of an online Asian genetic risk calculator on risk perception: Cancer-related distress and uptake of genetic counselling among Malaysian breast cancer patients (The ARiCa Study)
Presenter: HEAMANTHAA Padmanabhan
Session: Poster Display
Resources:
Abstract
23P - Consensus statements and expert recommendations for BRCAm breast cancer in the Asia-Pacific region (STREAM-AP)
Presenter: Soo Chin Lee
Session: Poster Display
Resources:
Abstract
24P - Germline genetic testing for hereditary cancer: A retrospective analysis in a single site referral centre in Malaysia
Presenter: Vivian Lee
Session: Poster Display
Resources:
Abstract
25P - Clinical presentations and prognostication of HER2-low breast cancer in Taiwan
Presenter: Bo-Fang Chen
Session: Poster Display
Resources:
Abstract